What role should artificial life play in medicine? Researchers from Denmark and the US explore the potential of hybrid peptide-DNA nanostructures for diagnosing and treating diseases.
Scientists have designed an AI tool that can rapidly decode a brain tumor’s DNA to determine its molecular identity during surgery — critical information that can guide treatment decisions.
Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.
A trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms.
Tumors sometimes seem to take on a life of their own, with cancer genes “striking out” in ring shapes. An international research team has new insights into this phenomenon.
Scientists at the University of Applied Sciences Krems (IMC Krems) show that CRISPR-Cas9 can also be used to inhibit viruses such as adenoviruses in cell cultures.
A model organism used in laboratories for the past 100 years has evolved so extensively that it may no longer be fit for purpose, according to a new study on bacterial strain Escherichia coli K-12.
According to an international group of researchers led by Leiden University Medical Center (LUMC), patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.
A new approach on the genetic tool CRISPR-Cas9 could reduce the risk of unwanted mutation, making it safer for use in humans, Dutch researchers have found.
Combining single-cell data with a self-learning algorithm reveals how structural changes in chromosomes can trigger cancer. This could pave the way for personalized cancer treatments.
Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way. The method showed promising results against various cancers in lab tests on mice.
A collaborative study has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL), and associated these with clinical outcomes.
Dutch global DNA/RNA technology solutions provider MolGen B.V., participates in the 24th Annual Conference of the European Society for Clinical Virology (ESCV) held in Manchester, UK.
Researchers identify critical spots on the genome where gene editing could cause an unwanted response, and they provide recommendations for safer approaches.
A new approach makes use of natural DNA repair machinery and provides a foundation for novel gene therapy strategies with the potential to cure a large spectrum of genetic diseases.
Blockchain is a digital technology that allows a secure and decentralized record of transactions. Now, researchers leveraged blockchain to give individuals control of their own genomes.
To develop new drugs, detailed knowledge about nature’s smallest biological building blocks is required. A new microscopy technique that allows proteins, DNA and other tiny biological particles to be studied in their natural state.
Around one in 500 men could be carrying an extra X or Y chromosome – most of them unaware – putting them at increased risk of diseases such as type 2 diabetes, atherosclerosis and thrombosis.
Computational approaches are being applied on enormous amounts of data from sequencing technologies to develop tools to help clinicians manage cancer more effectively.
SARS-CoV-2 has heavily impacted global society with high pressure on public health and economics. MolGen is proud to assist in relieving some of the pressure and support the testing framework.
A DNA test has been shown to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more-accurately than existing tests.
A worldwide consortium aims to equip researchers in low- and middle-income countries (LMICs) with cheap and accessible methods for sequencing large collections of bacterial pathogens.
Founded in 2018 as a DNA extraction chemistry company, Dutch company MolGen entered the market operating within the agricultural sector. At first, the company’s founders, Maarten de Groot, Wim van Haeringen and Niels Kruize, focused solely on this one industry, mainly developing and marketing advanced bulk chemistry kits for DNA/RNA extraction. These testing products and solutions successfully…
DNA / RNA extraction technology, system, products and kits for human and animal diagnostics, agriculture, aquaculture, pharma and biotech solutions provider MolGen B.V., announces the recent opening of its UK office. The new office is located at 6th Floor, South Quay Building, 189 Marsh Wall, London, E14 9SH. This expansion will enable the company to meet the rapidly increasing demand for…
Genomics England, a government owned company, recently announced a pilot programme of whole genome sequencing to screen for genetic diseases in 200,000 healthy seeming newborns. But should every newborn baby have their whole genome sequenced? Experts debate the issue in The BMJ. Extensive clinical evidence has shown that screening for genetic diseases saves lives, and research has shown that it…
